RE:What the hell....All this activity says to me is that they are mobilizing resources in a cost effective way to move TFC 1326 to market while they wait for 1067 to hit the shelves and some entity decides to acquire TFC 1326 in some form.
There is one thing clear, if they get TFC 1326 into consumer and dermatologist offices, and there is product uptake which corresponds to the strong clinicals, then any take out of this technology would be a deal which is different than a no proven sales scenario.
Ever watch Dragons den?
Who gives a rats butt who is compiling the marketing engine here. It doesn't take a biotech expert to develop marketing materials and develop an order fulfillment interface. Anyhow, I hear she is quite a smart person so we can count ourselves lucky that someone other than Howard is working on the file, especially since Michelle is gone.